ASCO 2019: Updated overall survival for treatment of locally advanced or metastatic triple-negative breast cancer

Peter Schmid | | KESÄKUU 6, 2019

Asiantuntija: Peter Schmid

In this MEDtalk Peter Schmid present updated data for overall survival from Impassion 130-study a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer.  

This 2nd IMpassion130 interim OS analysis confirming clinically meaningful OS benefit of this treatment combination.